The Readout Loud

396: A new trick for old science, and biotech VCs' scrambled playbook

395: Biotech investors' plea to Trump, and a busy M&A week

The biotech podcast episode centers on recent developments in the pharmaceutical industry, including the obesity drug market and mergers and acquisitions. It highlights the FDA's approval of Eli Lilly's new obesity pill, Foundayo, and the ensuing price competition with Novo Nordisk's Wigovi, also raising concerns about...

394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy

393: A conversation with the 'godfather' of biotech

392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA

391: Breaching the IBD efficacy ceiling, and sham surgeries

390: FDA turmoil, election intrigue, AI, and more

389: Hims' Super Bowl fallout, and the FDA reverses course

388: The FDA's refusal to review Moderna's mRNA flu vaccine

387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s

From Drug Story: Lipitor and Heart Disease

386: The high stakes for Huntington's patients

385: A measles outbreak and hospitals' financial troubles

384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen

383: JPM to bring more deals and happy CEOs

382: Biotech's year in review

381: The future of American science and a dispatch from ASH

380: A new top drug regulator and the future of psychedelics

379: How Mark Cuban plans to ‘f— up’ health care

378: Merck's heart disease win and the FDA's new drug regulator

This episode of The Readout Loud features a discussion on biotech news, including Pfizer's acquisition of Metsera, AbbVie ending its partnership with Calico Life Sciences, and Cochin Biosciences' drug trial results. The FDA's appointment of Richard Pazder as the head of the Center for Drug Evaluation and Research is al...